Affimed N V (AFMD)

Dec 21, 2024

Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World

Dec 21, 2024

Dec 17, 2024

Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Dec 17, 2024

Dec 17, 2024

Affimed Shares Fall 32% on Clinical Update - GuruFocus.com

Dec 17, 2024

Dec 17, 2024

Affimed stock plunges 23% on AFM24 study update - MSN

Dec 17, 2024

Dec 17, 2024

Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha

Dec 17, 2024

Dec 17, 2024

Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks

Dec 17, 2024

Dec 17, 2024

Affimed Reports Positive Clinical Update on - GlobeNewswire

Dec 17, 2024

Dec 17, 2024

Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan

Dec 17, 2024

Dec 14, 2024

Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World

Dec 14, 2024

Dec 13, 2024

Affimed (NASDAQ:AFMD) Short Interest Update - Defense World

Dec 13, 2024

Dec 09, 2024

AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN

Dec 09, 2024

Dec 09, 2024

Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page

Dec 09, 2024

Dec 09, 2024

Affimed to Host Investor Conference Call Highlighting - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan

Dec 09, 2024

Dec 09, 2024

Affimed's AFM28 Shows 40% Complete Remission Rate in Hard-to-Treat Leukemia Trial - StockTitan

Dec 09, 2024

Dec 08, 2024

Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan

Dec 08, 2024

Dec 08, 2024

Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire

Dec 08, 2024

Dec 06, 2024

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan

Dec 06, 2024

Dec 06, 2024

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Yahoo Finance

Dec 06, 2024

Dec 05, 2024

Affimed Announces Acimtamig and AlloNK® Combination Granted - GlobeNewswire

Dec 05, 2024

Dec 05, 2024

Affimed's Cancer Therapy Wins FDA RMAT Status After Striking 83% Response Rate in Lymphoma Trial - StockTitan

Dec 05, 2024

Nov 20, 2024

Affimed Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Nov 19, 2024

Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey

Nov 19, 2024

Nov 19, 2024

10 Best German Stocks To Buy Now - Insider Monkey

Nov 19, 2024

Nov 19, 2024

Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Nov 19, 2024

Nov 17, 2024

Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00 - Defense World

Nov 17, 2024

Nov 15, 2024

Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

Nov 15, 2024

Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat

Nov 15, 2024

Nov 15, 2024

Earnings call: Affimed reports promising results and strategic focus - Investing.com

Nov 15, 2024

Nov 15, 2024

Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 15, 2024

Nov 15, 2024

Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance

Nov 15, 2024

Nov 15, 2024

Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... By GuruFocus - Investing.com Canada

Nov 15, 2024

Nov 14, 2024

Affimed Reports Q3 2024 Financial Results and Updates - TipRanks

Nov 14, 2024

Nov 14, 2024

Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle

Nov 14, 2024

Nov 14, 2024

Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Affimed Faces Growing Losses Amid Financial Struggles - TipRanks

Nov 14, 2024

Nov 14, 2024

Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times

Nov 14, 2024

Nov 14, 2024

Affimed Q3 Revenue Drops 90%, but Net Loss Narrows as R&D Costs Decline | AFMD Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Affimed (AFMD) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Nov 13, 2024

Nov 07, 2024

Affimed to Report Third Quarter 2024 Financial Results and Corporate Update on November 14, 2024 - Marketscreener.com

Nov 07, 2024

Nov 07, 2024

Affimed (AFMD) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 07, 2024

Nov 06, 2024

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Affimed (AFMD) Sets Q3 2024 Earnings Call for Nov 14: Immuno-Oncology Updates Ahead | AFMD Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

Affimed (NASDAQ:AFMD) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Nov 06, 2024